A5068442652- Cancer therapeutics and mechanisms
- Bioactive Compounds and Antitumor Agents
- Photodynamic Therapy Research Studies
- Synthesis and biological activity
- Porphyrin and Phthalocyanine Chemistry
- Drug Transport and Resistance Mechanisms
- Boron Compounds in Chemistry
- Nanoplatforms for cancer theranostics
- DNA and Nucleic Acid Chemistry
- Synthesis and Biological Evaluation
- RNA Interference and Gene Delivery
- Radiopharmaceutical Chemistry and Applications
- Biochemical and Molecular Research
- Cancer-related Molecular Pathways
- Metal complexes synthesis and properties
- Carbohydrate Chemistry and Synthesis
- Nanoparticle-Based Drug Delivery
- Click Chemistry and Applications
- Synthesis and Characterization of Heterocyclic Compounds
- Reproductive Biology and Fertility
- DNA Repair Mechanisms
- Advanced biosensing and bioanalysis techniques
- Head and Neck Surgical Oncology
- Cancer, Hypoxia, and Metabolism
- Radiation Therapy and Dosimetry
Institute of Gene Biology
2019-2025
Ministry of Health
2018-2025
National Medical Research Center of Cardiology
2017-2025
State Scientific Center of the Russian Federation - Federal Medical Biophysical Center named after A.I. Burnazyan
2024
National Research Nuclear University MEPhI
2014-2024
Lomonosov Moscow State University
2018-2024
Deleted Institution
2024
Ministry of Health of the Russian Federation
2015-2023
ITMO University
2017-2023
Russian Cancer Research Center NN Blokhin
2012-2022
Mortality and disabilities as outcomes of cardiovascular diseases are primarily related to blood clotting. Optimization thrombolytic drugs is aimed at the prevention side effects (in particular, bleeding) associated with a disbalance between coagulation anticoagulation caused by systemically administered agents. Minimally invasive efficient approaches deliver agent site clot formation needed. Herein, we report novel nanocomposite prepared heparin-mediated cross-linking urokinase magnetite...
CDK8 and CDK19 Mediator kinases are transcriptional co-regulators implicated in several types of cancer. Small-molecule CDK8/19 inhibitors have recently entered or entering clinical trials, starting with breast cancer acute myeloid leukemia (AML). To identify other cancers where these novel drugs may provide benefit, we queried genomic transcriptomic databases for potential impact CDK8, CDK19, their binding partner CCNC. sgRNA analysis a panel tumor cell lines showed that most represented...
Previously, we demonstrated that the overexpression of antioxidant enzymes (SOD-1, SOD-2, Gpx-1, CAT, and HO-1), transcription factor NFE2L2, signaling pathway (PI3K/Akt/mTOR) contribute to cisplatin resistance SKOV-3/CDDP ovarian cells, treatment with quercetin (QU) alone has been shown inhibit expression these genes. The aim this study was expand previous data by examining efficiency reversing investigating underlying mechanism pre-treatment QU followed in same cancer cells. pre-incubation...
The review summarizes the chemistry of third generation photosensitizers, namely, derivatives natural bacteriochlorophyll a, for photodynamic treatment cancer. compounds this class strongly absorb light at lambda=770-850 nm. This unique property opens new therapeutic opportunities due to deeper tissue penetration light, thereby increasing photodamage tumor eradication. Analyzed are modifications that improve physico-chemical characteristics and enhance accumulation in tumors. Focusing on...
We describe the synthesis and properties of a new composite material based on heparin MIL-101(Fe) metal–organic framework.
Gold nanoparticles (GNPs) emerged as promising antitumor radiosensitizers. However, the complex dependence of GNPs radiosensitization on irradiation conditions remains unclear. In present study, we investigated impacts dose rate and photon energy damage pBR322 plasmid DNA exposed to X-rays in presence 12 nm, 15 21 26 nm GNPs. The greatest was observed for sensitizer enhancement ratio (SER) 2.74 ± 0.61 at 200 kVp with 2.4 mg/mL Reduction X-ray tube voltage 150 100 led a smaller effect. We...
Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase inhibitors (BCR-ABLi) are the mainstay of chronic myelogenous leukemia (CML) treatment. However, activation circumventing signaling pathways quiescence may limit BCR-ABLi efficacy. CDK8/19 Mediator kinases have been implicated in emergence non-genetic drug resistance. Dissecting effects pharmacological inhibition on CML survival response to BCR-ABLi, we found that a selective, non-toxic inhibitor (CDK8/19i) Senexin B (SenB) CDK8/19i...
Linear heteroareneanthracenediones have been shown to interfere with DNA functions, thereby causing death of human tumor cells and their drug resistant counterparts. Here we report the interaction our novel antiproliferative agent 4,11-bis[(2-{[acetimido]amino}ethyl)amino]anthra[2,3-b]thiophene-5,10-dione telomeric structures studied by isothermal titration calorimetry, circular dichroism UV absorption spectroscopy. New compound demonstrated a high affinity (Kass∼106 M−1) for antiparallel...